A Phase I/II Study for Analytic Validation of (89)Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

PURPOSE: Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism and is inadequate for diagnostic, prognostic, or predictive purposes. We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscint...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Pandit-Taskar, Neeta, O'Donoghue, Joseph A., Durack, Jeremy C., Lyashchenko, Serge K., Cheal, Sarah M., Beylergil, Volkan, Lefkowitz, Robert A., Carrasquillo, Jorge A., Martinez, Danny F., Fung, Alex Mak, Solomon, Stephen B., Gonen, Mithat, Heller, Glenn, Loda, Massimo, Nanus, David M., Tagawa, Scott T., Feldman, Jarett L., Osborne, Joseph R., Lewis, Jason S., Reuter, Victor E., Weber, Wolfgang A., Bander, Neil H., Scher, Howard I., Larson, Steven M., Morris, Michael J.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4668231/
https://ncbi.nlm.nih.gov/pubmed/26175541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0552
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars